1.525  -0.145 (-8.68%)		12-15 15:59
Open: 1.71 High: 1.71 Volume: 46,578		Pre. Close: 1.67 Low: 1.5 Market Cap: 12(M)

Short term
Mid term
Targets	6-month :	2.16	1-year :	2.52
Resists	First :	1.85	Second :	2.16
Pivot price	1.56
Supports	First :	1.33	Second :	1.01
MAs	MA(5) :	1.64	MA(20) :	1.51
	MA(100) :	2.02	MA(250) :	0
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	78.1	D(3) :	82.4
RSI	RSI(14): 45.8
52-week	High :	16.8	Low :	1.01

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ALUR ] has closed above bottom band by 42.6%. Bollinger Bands are 23.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	1.71 - 1.72	1.72 - 1.73
Low:	1.48 - 1.49	1.49 - 1.5
Close:	1.51 - 1.53	1.53 - 1.54

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon) and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company is headquartered in Natick, Massachusetts.

Tue, 25 Nov 2025
Allurion (NYSE: ALUR) Posts 23% Weight Loss, 14% Lean Mass Gain With Low-Dose Tirzepatide - Stock Titan

Thu, 20 Nov 2025
Chardan Capital Maintains Allurion Technologies (ALUR) Neutral Recommendation - Nasdaq

Tue, 18 Nov 2025
Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss - Business Wire

Mon, 17 Nov 2025
ALLURION TECHNOLOGIES, INC. SEC 10-Q Report - TradingView — Track All Markets

Wed, 12 Nov 2025
Earnings call transcript: Allurion Technologies sees Q3 revenue drop amid market shifts - Investing.com

Tue, 11 Nov 2025
Economic Insights on ALUR: What to Know About Recent Market Movement - timothysykes.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Outperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Devices
Shares Out	12 (M)
Shares Float	5 (M)
Held by Insiders	8.4 (%)
Held by Institutions	70.4 (%)
Shares Short	549 (K)
Shares Short P.Month	148 (K)

EPS	-16.21
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	-10.69
Profit Margin	-298 %
Operating Margin	-362.3 %
Return on Assets (ttm)	-65.4 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	-50.5 %
Gross Profit (p.s.)	0.85
Sales Per Share	1.4
EBITDA (p.s.)	-2.85
Qtrly Earnings Growth	0 %
Operating Cash Flow	-37 (M)
Levered Free Cash Flow	-17 (M)

PE Ratio	-0.1
PEG Ratio	0
Price to Book value	-0.15
Price to Sales	1.08
Price to Cash Flow	-0.51

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.